Mirabegron

Chemical formula: C₂₁H₂₄N₄O₂S Molecular mass: 396.506 g/mol PubChem compound: 9865528

Therapeutic indications

Mirabegron is indicated for:

Overactive bladder syndrome (OAB)

Population group: only adults (18 years old or older)

Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

50 mg once daily

Neurogenic detrusor overactivity

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Mirabegron is indicated for treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

For patients weighting 11 - <35 kg 3-10 ml once daily of oral suspension and for patients weighting ≥35 kg 25-50 mg tablet dose once daily

Contraindications

Mirabegron is contraindicated in the following cases:

Severe uncontrolled hypertension

Hypertensive crisis

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.